Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Lupus nephritis
•
Cyclophosphamide
•
Scleroderma
•
SLE
When do you consider Mesna for patients taking oral cyclophosphamide?
What dose do you use? Do you utilize oral or IV infusion Mesna?
Related Questions
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
How do you envision incorporating CAR-T therapy into your clinical practice?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How do you interpret a negative ANCA and a low positive PR3?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
